Explore 130+ historical metrics & ratios
Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
Cipher Pharmaceuticals is a Canadian specialty pharmaceutical company focused on dermatology and women's health products, primarily operating in Canada with selective international licensing arrangements. The company operates an asset-light model, licensing in-market products and out-licensing proprietary formulations, generating revenue through product sales in Canada and royalty streams from international partners. With 72% gross margins and minimal debt, the business model emphasizes high-margin branded dermatology products distributed through Canadian pharmacy channels.
Cipher operates a capital-efficient model by in-licensing established dermatology products for the Canadian market and out-licensing proprietary formulations internationally. Revenue derives from direct sales of branded prescription products through Canadian pharmacies and wholesalers, plus royalty streams from licensing agreements. The 72% gross margin reflects minimal manufacturing costs (contract manufacturing model) and pricing power in specialty dermatology where products address unmet needs with limited generic competition. Operating leverage is moderate as the company maintains a lean commercial infrastructure focused on dermatologist relationships rather than mass-market promotion.
New product licensing announcements - in-licensing established products for Canadian market or out-licensing proprietary formulations internationally
Canadian dermatology prescription trends - volume growth in core branded products driven by dermatologist adoption
Royalty revenue visibility - milestone payments and ongoing royalties from international licensing partners
Regulatory approvals - Health Canada approvals for new product launches or label expansions
Gross margin trajectory - product mix shift between higher-margin licensed products versus direct sales
Canadian pharmaceutical pricing pressure - provincial formulary negotiations and potential national pharmacare program could compress pricing power on branded products
Generic competition - patent expiries or biosimilar entry for licensed products could erode revenue streams, particularly for mature dermatology brands
Regulatory pathway changes - Health Canada approval timelines or requirements for specialty products could delay new product launches
Small market concentration - heavy reliance on Canadian market (population 40M) limits addressable market versus US-focused peers
Larger dermatology players (Valeant/Bausch, Galderma, LEO Pharma) have deeper resources for product acquisition and commercial infrastructure in Canada
Direct-to-consumer telehealth dermatology platforms disrupting traditional prescription channels and physician relationships
Licensing partner conflicts - international partners may prioritize larger markets over Canadian rights or compete with proprietary formulations
Limited financial flexibility - $0.3B market cap constrains ability to compete for large licensing deals or acquisitions against better-capitalized competitors
Working capital volatility - inventory management for specialty products and accounts receivable timing with Canadian wholesalers can create quarterly cash flow fluctuations
Currency exposure - licensing revenue from international partners denominated in foreign currencies creates translation risk, though Canadian operations provide natural hedge
low - Prescription dermatology products address medical conditions (acne, rosacea, psoriasis) with consistent demand regardless of economic conditions. Canadian universal healthcare coverage insulates prescription volumes from consumer spending fluctuations. However, discretionary cosmetic dermatology products may see modest sensitivity to consumer confidence. Revenue growth driven more by product lifecycle management and new launches than GDP growth.
Rising rates have modest negative impact on valuation multiples for specialty pharma stocks trading at premium P/E ratios, as investors rotate toward higher-yielding fixed income. However, minimal debt (0.12 D/E) means negligible direct financing cost impact. The company's 6.9% FCF yield becomes more attractive in low-rate environments. Rate changes primarily affect relative valuation versus bonds rather than operational performance.
Minimal - The company operates with low leverage (0.12 D/E) and strong cash generation (34.6% net margin, positive operating cash flow). Credit conditions have limited direct impact on operations. Indirectly, tighter credit could affect pharmacy working capital or wholesaler financing, but Canadian pharmaceutical distribution is stable. No meaningful exposure to credit-dependent customers or financing-intensive growth plans.
value - The stock trades at 5.7x P/S with 6.9% FCF yield, attracting value investors seeking cash-generative specialty pharma at reasonable multiples. The 42% one-year return suggests momentum interest, but negative net income growth (-43.4%) despite revenue growth (+57.7%) indicates margin compression concerns. Dividend-focused investors may be attracted to cash generation, though small-cap liquidity limits institutional ownership. The asset-light licensing model appeals to investors seeking pharmaceutical exposure without manufacturing or R&D capital intensity.
high - Small-cap specialty pharma with $0.3B market cap exhibits elevated volatility driven by binary events (licensing deals, regulatory approvals, quarterly earnings surprises). Limited float and institutional ownership amplify price swings. The 42% one-year return with -3.9% six-month return demonstrates momentum reversals. Sector rotation between growth and value styles creates additional volatility for specialty pharma names.